Objectives: To describe and compare the use and effectiveness of a single intra-articular injection (IA) of triamcinolone acetonide (TA), hyaluronan (HA), and a combination of both (TA+HA) in police working dogs with natural occurring hip osteoarthritis (OA).

Study Design: Prospective, randomized, single-blinded study.

Sample Population: Thirty animals with naturally occurring hip OA.

Methods: Animals were randomly divided in three groups: GT, treated with 20 mg of TA per hip joint; GH, treated with treated 20 mg of HA per hip joint; and GTH, treated with a combination of 20 mg of TA and 20 mg of HA per hip joint. Response to treatment, measured by the Canine Brief Pain Inventory (divided in Pain Interference Score—PIS and Pain Severity Score—PSS) and the Hudson Visual Analog Scale (HVAS), was evaluated in seven different time points: T0 (before treatment), T1 (after 15 days), T2, T3, T4, T5, and T6 (after 1, 2, 3, 4, and 5 months, respectively). Results were compared using a Kruskal-Wallis test or a Wilcoxon signed ranks test, and p < 0.05 was set.

Results: Comparing results of the different time points considered with T0, significant differences were registered in GH at T1 for HVAS (p = 0.03) and PIS (p = 0.04); and in GTH at T1 (p = 0.05 for HVAS and p < 0.05 for PIS), T2 (p < 0.04 for PIS), T3 (p < 0.03 for HVAS and p = 0.05 for PIS), T4 (p < 0.03 for HVAS and p < 0.05), and T5 (p < 0.05 for HVAS). No significant differences were found between groups when comparing scores in each time point. Individual treatment is considered successful with a reduction of ≥1 for PSS or ≥2 for PIS. In GTH, treatment was successful in four animals between T1 and T5 (40%, n = 10) and three at T6–T7 (30%, n = 10) for PSS and three animals of GTH at T1 (30%), two at T2 (20%), three between T3 and T4 (30%), and two between T5 and T7 (20%).

Conclusions and Clinical Relevance: This study provides direct information on the use of these treatment modalities in patients with hip OA. Intra-articular injection with TA and HA may be a treatment option for dogs with naturally occurring OA, particularly when simultaneously used, as they provide significant improvements of PIS and HVAS scores. Individual scores improved in some animals with PIS, PSS, and HVAS.

目的：描述和比较单次关节内注射（IA）曲安奈德（TA）、透明质酸（HA）以及两者的组合（TA+HA）在具有自然髋关节的警用工作犬中的使用和有效性骨关节炎（OA）。

研究设计：前瞻性、随机、单盲研究。

样本群体：三十只患有自然发生髋关节骨关节炎的动物。

方法：将动物随机分为三组：GT组，每个髋关节接受20mg TA治疗；GT组，每个髋关节接受20mg TA治疗；GT组，每个髋关节接受20mg TA治疗； GH，每个髋关节接受 20 毫克 HA 治疗；和 GTH，每个髋关节联合使用 20 毫克 TA 和 20 毫克 HA 进行治疗。通过犬类简短疼痛量表（分为疼痛干扰评分 - PIS 和疼痛严重程度评分 - PSS）和哈德逊视觉模拟量表（HVAS）测量对治疗的反应，在七个不同的时间点进行评估：T0（治疗前）， T1（15 天后）、T2、T3、T4、T5 和 T6（分别为 1、2、3、4 和 5 个月后）。使用 Kruskal-Wallis 检验或 Wilcoxon 符号秩检验比较结果，并设置 p < 0.05。

结果：将不同时间点的结果与 T0 进行比较，T1 时 GH 的 HVAS (p = 0.03) 和 PIS (p = 0.04) 出现显着差异；在 GTH 中，T1（HVAS 的 p = 0.05，PIS 的 p < 0.05）、T2（PIS 的 p < 0.04）、T3（HVAS 的 p < 0.03，PIS 的 p = 0.05）、T4（p % HVAS 为 3C 0.03，p < 0.05），以及 T5（HVAS 为 p < 0.05）。比较每个时间点的分数时，组间没有发现显着差异。 PSS 降低 ≥1 或 PIS 降低 ≥2 则认为个体治疗是成功的。在 GTH 中，T1 至 T5 期间的四只动物（40%，n = 10）和 T6-T7 的三只动物（30%，n = 10）的 PSS 治疗成功，T1 的三只 GTH 动物（30%）治疗成功，两只T2 时 (20%)，T3 和 T4 之间有 3 个 (30%)，T5 和 T7 之间有 2 个 (20%)。

结论和临床相关性：本研究提供了髋关节 OA 患者使用这些治疗方式的直接信息。关节内注射 TA 和 HA 可能是患有天然 OA 的狗的一种治疗选择，特别是同时使用时，因为它们可以显着改善 PIS 和 HVAS 评分。一些使用 PIS、PSS 和 HVAS 的动物的个体得分有所提高。